Skip to content
Clinical Trials – home

Complex Oncological Center - Shumen EOOD

Research site

Bulgaria Ulitsa Vasil Aprilov 63, 9705 Shumen, Bulgaria

  • 6 trials recruiting
  • Breast cancer metastatic · Bladder cancer · Breast cancer
  • Adult patients

About Specializations

Complex Oncological Center - Shumen EOOD in Shumen, Bulgaria specialises in clinical trials of conditions such as Breast cancer metastatic, Bladder cancer, Breast cancer, Asthma, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms – Breast Cancer Research

The Department of Medical Oncology at Complex Oncological Center - Shumen EOOD focuses on ER+/HER2- Early Breast Cancer and metastatic breast cancer, aiming to improve outcomes with new endocrine strategies.

  • Assessing novel oral selective estrogen receptor degraders
  • Combining endocrine therapy with CDK4/6 inhibition
  • Preventing recurrence in early‑stage disease

With three active studies and eight investigators, the site is evaluating innovative agents such as elacestrant and camizestrant to enhance treatment effectiveness for patients in Bulgaria and Europe.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ulitsa Vasil Aprilov 639705 ShumenBulgaria
Recruiting now
6 trials
Conditions studied
19

More sites in ShumenBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

25 clinical trials

Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Bladder cancer

Recruiting

Long‑Term Follow‑Up of Mitomycin (UGN‑103) Treatment in Patients with Recurrent Low‑Grade Intermediate‑Risk Non‑Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study of UGN-104 (mitomycin) treatment for patients with low-grade upper tract urothelial cancer

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Asthma

Not recruiting

Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

A Study of Inhaled Fexlamose for Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE
  • Sponsor:Aer Therapeutics Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.